NPY

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, NPY Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated NPY data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher NPY Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NPY expression acts as an unfavorable survival marker.

BLCA are the cancer types where NPY Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
BLCAOSMedianAll0.0900.710<.00136view →
Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

NPY–BLCA (OS)

Kaplan–Meier survival curve for NPY mutant vs wild-type samples in BLCA.

Open the BLCA breakdown →

Exploration